Answers are grounded in this paper and cite their sources.
Retrospective cohort study links vitamin B12 deficiency with elevated homocysteine to higher retinal vein occlusion risk, suggesting it’s a modifiable risk factor.
Purpose: To evaluate whether vitamin B 12 deficiency with elevated homocysteine is associated with increased risk of retinal vein occlusion (RVO). Methods : A retrospective cohort study was conducted using the TriNetX US Collaborative Network (August 2005—August 2025). Adults (≥18 years) with vitamin B 12 deficiency (International Classification of Diseases, Tenth Revision code D51.0-D51.9) and hyperhomocysteinemia (>15.00 µmol/L) were matched in a 1:1 ratio to controls without B 12 deficiency and with homocysteine status unrestricted, using propensity scores for age, sex, race, ethnicity, body mass index, hypertension, diabetes, ischemic heart disease, and nicotine dependence. Patients with pre-index RVO were excluded. The primary outcome was incident RVO (central or branch) over 10 years, analyzed with risk ratios, odds ratios, hazard ratios, and Kaplan-Meier cumulative incidence curves. Results : After matching and exclusion of patients with prior RVO, 10 161 individuals were included (5070 with B 12 deficiency and hyperhomocysteinemia, 5091 controls). The cohorts were well-balanced across demographics and comorbidities. Incident RVO occurred in 32 patients (0.63%) with B 12 deficiency and hyperhomocysteinemia compared with 15 patients (0.29%) among the control group, corresponding to a statistically significant increased risk (risk ratio, 2.142 [95% CI, 1.162-3.951]; odds ratio, 2.149 [95% CI, 1.163-3.974]; both P = .012). Kaplan-Meier curves demonstrated a higher cumulative incidence of RVO in the B 12 deficiency and hyperhomocysteinemia cohort (log-rank χ² = 7.551, P = .006; hazard ratio, 2.306 [95% CI, 1.249-4.260]). Conclusions : Vitamin B 12 deficiency with hyperhomocysteinemia was associated with an increased RVO risk. These findings highlight a modifiable risk factor, and prospective studies are needed to assess causality and evaluate whether correction of vitamin B 12 deficiency or hyperhomocysteinemia reduces RVO risk.
No takes yet. Share an insight, caveat, or question.
Shmushkevich et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: